2 weeks Ago By ABMN Staff
Segall Bryant & Hamill LLC purchased a new stake in shares of Merck & Co., Inc. ( NYSE:MRK – Free Report ) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The fund purchased 20,922 shares of the company’s stock, valued at approximately $2,376,000. Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. AM Squared Ltd purchased a new position in Merck & Co.
, Inc. in the third quarter valued at approximately $34,000. Itau Unibanco Holding S.
A. purchased a new position in shares of Merck & Co., Inc.
in the 2nd quarter valued at $39,000. Peterson Financial Group Inc. acquired a new position in shares of Merck & Co.
, Inc. during the 3rd quarter valued at $36,000. Abich Financial Wealth Management LLC lifted its holdings in shares of Merck & Co.
, Inc. by 121.8% during the 2nd quarter.
Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after acquiring an additional 179 shares in the last quarter. Finally, Quarry LP purchased a new stake in Merck & Co., Inc.
during the 2nd quarter worth $42,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth MRK has been the topic of a number of recent research reports. Morgan Stanley reduced their price objective on Merck & Co., Inc.
from $130.00 to $123.00 and set an “equal weight” rating on the stock in a research note on Friday, November 1st.
Barclays lowered their price objective on shares of Merck & Co., Inc. from $142.
00 to $140.00 and set an “overweight” rating for the company in a research report on Monday, October 7th. Guggenheim reduced their target price on shares of Merck & Co.
, Inc. from $137.00 to $130.
00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. UBS Group lowered their price target on shares of Merck & Co., Inc.
from $142.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, October 9th.
Finally, Daiwa America cut shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 11th.
One equities research analyst has rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Merck & Co., Inc.
presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.86. Merck & Co.
, Inc. Price Performance Shares of NYSE:MRK opened at $99.18 on Friday.
The company has a market cap of $250.89 billion, a PE ratio of 20.79, a P/E/G ratio of 1.
43 and a beta of 0.40. Merck & Co.
, Inc. has a fifty-two week low of $94.48 and a fifty-two week high of $134.
63. The firm has a 50-day simple moving average of $107.11 and a 200 day simple moving average of $117.
83. The company has a quick ratio of 1.15, a current ratio of 1.
36 and a debt-to-equity ratio of 0.79. Merck & Co.
, Inc. ( NYSE:MRK – Get Free Report ) last posted its earnings results on Thursday, October 31st. The company reported $1.
57 EPS for the quarter, beating the consensus estimate of $1.50 by $0.07.
The company had revenue of $16.66 billion during the quarter, compared to analyst estimates of $16.47 billion.
Merck & Co., Inc. had a return on equity of 36.
42% and a net margin of 19.23%. The business’s revenue was up 4.
4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.13 earnings per share.
On average, sell-side analysts anticipate that Merck & Co., Inc. will post 7.
73 EPS for the current year. Merck & Co., Inc.
Increases Dividend The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 8th. Shareholders of record on Monday, December 16th will be paid a $0.81 dividend.
This represents a $3.24 dividend on an annualized basis and a yield of 3.27%.
This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.
77. The ex-dividend date of this dividend is Monday, December 16th. Merck & Co.
, Inc.’s dividend payout ratio (DPR) is presently 64.57%.
Merck & Co., Inc. Company Profile ( Free Report ) Merck & Co, Inc operates as a healthcare company worldwide.
It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. Featured Stories Receive News & Ratings for Merck & Co.
Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc.
and related companies with MarketBeat.com's FREE daily email newsletter ..
